目的 利用“中国肾脏病大数据应用创新联盟大数据平台”（以下简称“中国肾脏病大数据平台”）提取真实世界数据，观察“益肾清利活血方”对慢性肾脏病1-2期蛋白尿的治疗作用。方法 收集2015年1月1日至2020年6月1日于“中国肾脏病大数据应用平台”随访超过12个月的慢性肾脏病1-2期非肾病范围内蛋白尿患者共125例，比较治疗6个月、治疗12个月的24 h尿蛋白定量及疗效分析。结果 与治疗前比较，治疗6个月后总有效率为65.6%，经治12个月后总有效率为75.2%；治疗6个月后的24 h尿蛋白定量水平（0.96 g）较基线水平（1.22 g）下降（P < 0.05），治疗12个月后的24 h尿蛋白定量（0.77 g）显著下降（P < 0.01），控制蛋白尿疗效随着疗程延长而升高。此外，我们观察到其中32例患者有前后肾功能对比，其中尿素氮、血肌酐较治疗前均有所下降，估算的肾小球滤过率有所上升，但均无统计学差异，即患者肾功能保持相对稳定。结论 “益肾清利活血方”可以降低慢性肾脏病1-2期患者尿蛋白水平、维持肾功能稳定，值得临床推广。

Objective Based on the real-world study, to extract data from “China Kidney disease Big data Application platform”, to observe the therapeutic effect of Professor Sun Wei"s “Yishen Qingli Huoxue Recipe” on proteinuria of chronic kidney disease 1-2 stages.Methods A total of 125 patients with proteinuria of CKD1-2 stages were admitted to the Department of Nephrology, Jiangsu Province Hospital of Traditional Chinese Medicine from Jan 1, 2015 to Jun 1, 2020, whom were observed over 12 months. After treatments, the 24 h UTP and BUN, Scr were measured and analyzed.Results The total effective rate was 65.6% after 6 months treatments, as well as was 75.2% after 12 months treatments. Compared with the baseline, the 24 h UTP was declined from 1.22 g to 0.96 g after 6 months" treatment (P<0.05), and decline further to 0.77 g after 12 months" treatments (P<0.01). Otherwise, we observed renal function of 32 patients with integrated records. The BUN, Scr were decreased while eGFR was increased after treatments without statistical significance.Conclusion “Yishen Qingli Huoxue Recipe” could reduce the 24 h UTP, and stabilize renal function in patients with CKD 1-2 stages. It is worth promoting applications in clinic.